HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

Clinical trial pipeline · Data from ClinicalTrials.gov

See which HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

TerminatedPhase 3

NCT06038539

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemo…

To compare the efficacy and safety of PERT-IJS (Proposed biosimilar Pertuzumab) plus trastuzumab and chemotherapy (carboplatin and docetaxel) versus EU-Perjeta…

India55 participantsStarted 2025-01-06

Treatment: PERT-IJS plus trastuzumab, carboplatin and docetaxel, Perjeta plus trastuzumab, carboplatin and docetaxel